Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Urinary Prostaglandin as a Potential Predictive Marker for Thiazide-induced Hyponatremia: a Prospective Cohort Study (The PROPHECY Study)

NCT05542056 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.

NCT NCT05542056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05542056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Urinary Prostaglandin as a Potential Predictive Marker for Thiazide-induced Hyponatremia: a Prospective Cohort Study (The PROPHECY Study)
Lead sponsor
University Hospital, Basel, Switzerland
Phase
Observational
Overall status
Recruiting
Start date
September 26, 2022
Completion date
July 31, 2026
Enrollment
232 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

thiazide-induced hyponatremia (tih)